Idorsia Ltd (CH:IDIA)
:IDIA
Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF3.71
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.71
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF1.21 - CHF4.85
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF931.81M
Enterprise ValueCHF1.96B
Total Cash (Recent Filing)CHF94.70M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Jul 28, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding253,983,460
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside28.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.54
Revenue Forecast (FY)CHF224.62M
Bulls Say, Bears Say
Bulls Say
Geographic Partnerships And RevenueExclusive distribution agreements across the Middle East and Latin America, including a license in Brazil, are expected to generate milestone payments, supply revenue, and royalties that strengthen near-term cash and reduce financing needs.
Leadership And GovernanceReturn of an experienced CEO and planned additions of independent directors signal a strategic shift toward prioritizing revenue growth and optimizing company value.
Pediatric Clinical ResultsPhase 2 pediatric data for QUVIVIQ showed a clear dose-dependent increase in total sleep time and a favorable safety profile in children down to age ten, supporting potential expansion into a high-need pediatric market.
Bears Say
Clinical And Regulatory Execution RiskRegulatory approval hinges on proving meaningful kidney improvement in pivotal studies, leaving valuation exposed to the risk of late-stage trial failure or inconclusive results.
Commercialization Partner RiskAbsence of a confirmed North American partner for aprocitentan creates material execution risk that could delay market entry and limit value capture in a major territory.
Guidance And Cost PressureDeclining visibility on guidance combined with higher operating expenses has prompted lower analyst targets and could pressure the stock if cost controls and revenue gains do not materialize.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF1.21 and its highest was CHF4.85 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF931.81M.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Jul 28, 2026 which is in 87 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Apr 28, 2026. The company reported -CHF0.14 earnings per share for the quarter, beating the consensus estimate of -CHF0.185 by CHF0.045.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.14.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 253,983,460 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.14 in its last earnings report, beating expectations of -CHF0.185. Following the earnings report the stock price went up 4.782%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▲(28.03% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---